Production (Stage)
Coeptis Therapeutics Holdings, Inc.
COEP
$8.23
-$0.13-1.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.00% | -50.45% | -50.58% | -50.25% | -60.24% |
| Depreciation & Amortization | 0.00% | 0.00% | 50.00% | 200.00% | 200.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.05% | -53.22% | -47.25% | -10.22% | -28.56% |
| Operating Income | 37.40% | 53.22% | 47.25% | 10.22% | 28.56% |
| Income Before Tax | 30.74% | 48.85% | 43.18% | 18.27% | 38.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.74% | 48.85% | 43.18% | 18.27% | 38.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.49% | 53.85% | 43.18% | 18.27% | 38.11% |
| EBIT | 37.40% | 53.22% | 47.25% | 10.22% | 28.56% |
| EBITDA | 39.89% | 55.81% | 49.58% | 10.79% | 29.75% |
| EPS Basic | 61.42% | 71.01% | 65.89% | 54.30% | 66.48% |
| Normalized Basic EPS | 65.71% | 73.41% | 66.43% | 54.80% | 66.74% |
| EPS Diluted | 61.42% | 71.01% | 65.89% | 54.30% | 66.48% |
| Normalized Diluted EPS | 65.71% | 73.41% | 66.43% | 54.80% | 66.74% |
| Average Basic Shares Outstanding | 52.59% | 50.32% | 69.45% | 81.98% | 82.33% |
| Average Diluted Shares Outstanding | 52.59% | 50.32% | 69.45% | 81.98% | 82.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |